WHWK news

Whitehawk Therapeutics appointed Dr. Vijay Iyengar to its board, effective Sept. 9, bringing over 20 years of oncology and corporate strategy experience. This addition bolsters the company's leadership as it advances its ADC pipeline and aims to commercialize treatments.

Whitehawk Therapeutics reported Q2 2026 financials highlighting a cash balance of $190.0 million and clinical progress. The company's progress is overshadowed by a material decrease in revenue compared to the previous year.

Whitehawk Therapeutics entered into an option agreement with Hangzhou DAC for access to CPT113 for up to five additional ADC programs, with anticipated IND submissions over the next 12-24 months. The expansion validates the company's CPT113 linker-payload technology platform and demonstrates clinica…